Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.

Antonio Costanzo Mar Llamas VelascoGabriella FabbrociniAldo CucciaRaquel Rivera-DíazKristian Gaarn Du JardinIsmail KasujeeLluis L Puig Y José Manuel Carrascosa

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

TIL 100 mg treatment after 24 weeks in conditions close to real clinical practice showed a quick and high improvement in psoriasis signs and HRQoL. Patient reported improvements in sleep outcomes and work productivity, relevant benefits and high treatment satisfaction. The safety profile was favourable and consistent with phase III trials.

Keyphrases

clinical practice
patient reported
phase iii
end stage renal disease
sleep quality
newly diagnosed
chronic kidney disease
ejection fraction
early onset
metabolic syndrome
adipose tissue
combination therapy
patient reported outcomes
atopic dermatitis
phase ii